<h1>Pharma firm and government form 51/49 joint venture to build generic drug plant, commercial supply targeted Q3 FY28</h1> A pharmaceutical company and the government have agreed to form a joint venture headquartered in the country to build a manufacturing facility for generic medicines, with the company holding 51% and the state instrumentality 49%; governance will be by a jointly constituted board and capital and operational contributions will follow shareholding ratios. Establishment is targeted by Q3 FY26, construction thereafter, and commercial supply by Q3 FY28 subject to regulatory approvals. The government committed to minimum purchases of USD 25 million in 2026 and 2027 from the company's existing facilities; the JV may also export regionally.